Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

@article{Deacon2012GlycaemicEO,
  title={Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.},
  author={Carolyn F Deacon and Edoardo Mannucci and Bo Ahr{\'e}n},
  journal={Diabetes, obesity & metabolism},
  year={2012},
  volume={14 8},
  pages={762-7}
}
AIMS During recent years, two strategies of incretin-based therapy [glucagon-like peptide-1 (GLP-1) receptor agonism and dipeptidyl peptidase-4 (DPP-4) inhibition] have entered the market for pharmacological management of type 2 diabetes. A main indication for this therapy is as add-on to on-going metformin therapy in subjects with type 2 diabetes who have insufficient glycaemic control with metformin alone. The aim of this study was to compare improvements in glycaemic control and changes in… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 46 references

Blocking GLP-1 action with exendin (939) to determine the contribution of GLP-1 to the insulinotropic effects of the DPP-4 inhibitor vildagliptin

A Nauck, J Kind, CF Deacon
Diabetologia • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…